Lead Product(s): Fezolinetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ESN364
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2021
The SKYLIGHT 1 and SKYLIGHT 2 pivotal Phase III trials reached all co-primary endpoints, showing a significant reduction in the incidence and severity of mild to extreme VMS from baseline to week 4 and week 12 for women taking fezolinetant 30 and 45 mg once-daily.